New Delhi: Over the past few years, India has been solidifying its position as the world’s IVF/infertility treatment capital, which will be further aided by the government’s renewed focus on boosting medical tourism in the country. With the advent of technological advancements and the Assisted Reproductive Technologies (ART) Bill, the government, enterprise and individual stakeholders of the industry have been spearheading unprecedented growth of the fertility industry in India.
In the spirit of further strengthening the collaborative efforts of the industry stakeholders, ETHealthworld presents the third edition of the Fertility Conclave in association with presenting partner Bharat Serums and Vaccine Limited (BSV), powered by Oasis Fertility, gold partner InterMedics, and supporting partners Ferty9, Santaan Fertility, Gunjan IVF World, and Allwin Medical Devices on February 21. At the Fertility Conclave 2023, key players of the fertility ecosystem including fertility experts, researchers, pharmaceutical and lifescience companies, and policymakers will come together to deliberate on the fertility industry’s medical, legal and financial issues.
The guest of honour for the conclave will be N Nawin Sona, Principal Secretary, Public Health Department, Government of Maharashtra, who will share his insights on ‘Changes, Challenges & Opportunities in Public Health: Fertility.’
Panel discussions:
The summit will host influential leaders from the fertility sector who will meet and deliberate on some of the most pertinent issues in the industry. The focus will be on the future of fertility and the changes, challenges and opportunities faced by the industry to map the road ahead.
The first fertility panel will be on ‘ART & Surrogacy Laws in India: The Future of Fertility’. Panellists will be sharing their insights on the role played by the government and other associations in ensuring access to quality infertility treatment, the impact and change led by the ART Bill 2021, the best practices and risk management in fertility labs and centres, and accrediting for patient safety in ART/IVF centres. The panel will consist of Dr Nitiz Murdia, Expert Member, National ART and Surrogacy Board, Co-Founder and Managing Director, Indira IVF Hospital Pvt Ltd, Dr Nandita Palshetkar, President, ISAR, Dr Kamini A Rao, Founder Chairperson, Medline Academics, Sanjiv Navangul, Managing Director and CEO, BSV, and Amit Karkhanis, Advocate High Court and Medicolegal Expert. The session will be moderated by Vikas Dandekar, Editor, Pharma and Healthcare, ET Prime.
The subsequent panel discussion will be on ‘Investments in Fertility: Expectations, Opportunities and Challenges’ to discuss the vital role of hard and soft investments, finances for credibility, entrepreneurs versus investors, and reproductive technology in the fertility industry. The panellists for this session include Dr Aniruddha Malpani, Founder, Malpani Infertility Clinic and Malpani Ventures, Dr Kshitiz Murdia, Co-Founder and Chief Executive Officer, Indira IVF, Vinesh Gadhia, Senior Partner and Chief Executive Officer, BlackCap Equity Management, Kiran Gadela, Co-Founder and Managing Director, Oasis Fertility, and Vishwanath Swarup, Chief Operating Officer, BSV. The sessions will be moderated by Muqbil Ahmar, Executive Editor, The Economic Times (ETCIO).
This will be followed by a special address by Dr Indira Hinduja, In Charge, Hinduja IVF Centre, PD Hinduja National Hospital and MRC, on ‘Overcoming Obstacles in the Journey of IVF Industry.’
The third session of the day will be moderated by Dr Chinmay M Pataki, Director and Co-Owner, Akruti IVF Centre LLP, to discuss the emerging position of India as the IVF/infertility treatment capital of the world. In this session on ‘IVF Medical Tourism, Is It HereTo Stay?’ panel members Dr Mugdha Raut, Co-Founder and Partner, Dr Raut’s Centre for Reproductive Immunology and Dr Richa Jagtap, Co-Medical Director, India and Consultant Reproductive Medicine, ART Fertility Clinics, will deliberate the need of infrastructure for the upcoming boom in the fertility industry and the impending effect of medical tourism, and analyse the role of COVID-19 in delaying the boom of IVF medical tourism in India.
A partner presentation will follow the discussion on medical tourism by Dr Krishna Chaitanya Mantravadi, Scientific Head and Clinical Embryologist, Oasis Fertility, on ‘IVM (in vitro maturation),’ followed by Gunjan Gupta, Founder & Medical Director, Gunjan IVF World’s presentation on ‘IVF: The Success Mantra.’
The partner presentations will be succeeded by ‘Fireside Chat: Infertility And Public Health’ between Dr Jaydeep D Tank, IVF Consultant and President-Elect, FOGSI, Dr Prof (Col) Pankaj Talwar VSM, Director, Medical Services, Birla Fertility and IVF and President-Elect, IFS, and moderator Prabhat Prakash, Senior Digital Content Creator, ETHealthworld.
The fireside chat will be succeeded by partner presentations, Dr C Jyothi Budi, Medical Director, Ferty9 will present on ‘Fertility Experts & Embryologists – Engines of the Growth story,’ followed by a presentation by Dr Satish Prasad Rath, Founder, Santaan Fertility Centre and Research Institute on ‘AI-Powered and Innovation Driven Fertility Care,’ and Dhiren Mehta, CEO, Allwin Medical Devices on ‘Manufacturing in India for the Globe.’
In the final session of the day on ‘Discussing Advancements: Time Lapse, PRP Treatment, Stem Cell Treatment & More,’ the discussion between panel members Dr Keshav Malhotra, Lab Director, Rainbow IVF, Second Vice Chairman of Embryology, ISAR and Co-Chair SIG Embryology, ASPIRE, Dr PM Gopinath, Director & Senior Consultant, Institute of OBG and IVF and SIMS Hospital, Dr Prabhakar Singh, Co-Founder and Director, Nimaaya Women’s Centre For Health, Dr Sweta Agarwal, Director – Fertility and Gynaecology, Southern Gem Hospital, and Dr Duru Shah, Director, Gynaecworld – The Centre for Women’s Health & Fertility, will be moderated by Muqbil Ahmar, Executive Editor, The Economic Times (ETCIO). The session will conclude the panel discussions with insights on the advancements that have helped in infertility treatment, the enhancement in patient experience, the adaptability, cost impact and widespread acceptance among doctors and embryologists of empire implantation genetic testing, combining clinical and tech perspectives, and the need of the hour for India’s fertility industry.
The Fertility Conclave 2023 will conclude with ETHealthworld’s National Fertility Awards to acknowledge the efforts and hard work of industry stakeholders who have been challenging adversities to ensure their patients become parents meanwhile also pushing the Industry to achieve its maximum potential.